Three randomized phase III trials have now conclusively proven that exposure to a PD-1
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …

Head and neck squamous cell carcinoma (HNSCC) is a relatively common cancer (1). While
many patients with locally advanced disease are cured with some combination of surgery …

Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …

Background Locoregionally advanced, recurrent, and metastatic squamous cell carcinomas
of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic …

Background Recently, enormous progress in cancer therapy has been achieved by the use
of immune checkpoint inhibitors. Activating the body's own immune system has added a …

Immunotherapy has changed the treatment landscape of Head and Neck cancer (HNC).
Different immune checkpoint inhibitors targeting PD-1/PD-L1 axis have been approved for …

Abstract Purpose of Review Discussion of current strategies targeting the immune system
related to solid tumors with emphasis on head and neck squamous cell carcinoma …

Abstract Purposeof Review Head and neck cancer (HNC) comprises a group of
malignancies, amongst which squamous cell carcinoma accounts for more than 90% of the …

Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. While this approach …

Preclinical data suggest that head and neck squamous cell carcinoma (HNSCC) is a
profoundly immunosuppressive disease, characterized by abnormal secretion of …